June 10, 2022
Bulletin interne de l'Institut Pasteur
The Institut Pasteur and MSDAVENIR sign a partnership agreement to improve strategies for controlling the spread of vector-borne viral diseases like Zika
On June 7, the Institut Pasteur and pharmaceutical company MSD France's health research endowment fund MSDAVENIR signed a major partnership agreement to anticipate the response to future vector-borne viral outbreaks. The partnership funding amounting to more than €1.7 million will support the INTRANZIGEANT project led by doctors Louis Lambrechts, Head of the Insect-Virus Interactions Unit and Xavier Montagutelli, Head of the Mouse Genetics Laboratory at the Institut Pasteur. This agreement is the first in a new wave of investments by MSDAVENIR amounting to €42 million spread over three years.